Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients
Background and aims: miRNA-124 (miR-124) expression was known to be downregulated in patients with pancreatic ductal adenocarcinoma (PDAC). Downregulation of miR-124 was significantly associated with poor prognosis in patients with PDAC. Recent studies have shown that circulating miRNAs could be the...
Gespeichert in:
| Veröffentlicht in: | British journal of biomedical science 2016-10, Vol.73 (4), p.152-157 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 157 |
|---|---|
| container_issue | 4 |
| container_start_page | 152 |
| container_title | British journal of biomedical science |
| container_volume | 73 |
| creator | Sun, BoLin Liu, Xiaogang Gao, Yewu Li, Li Dong, ZhenLing |
| description | Background and aims: miRNA-124 (miR-124) expression was known to be downregulated in patients with pancreatic ductal adenocarcinoma (PDAC). Downregulation of miR-124 was significantly associated with poor prognosis in patients with PDAC. Recent studies have shown that circulating miRNAs could be the potential biomarkers for invasive diagnostic as well as prognostic purposes. The purpose of the current study was to characterise the serum miR-124 levels and assess the clinical significance of serum miR-124 in patients with PDAC.
Methods: Using quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) assays, serum miR-124 levels were determined in serum from 126 patients with PDAC (53 resectable pancreatic cancer and 73 unresectable pancreatic cancer), 28 chronic pancreatitis patients and 47 healthy control individuals. The prognostic significance of miR-124 and other clinicopathological variables was determined using univariate and multivariate analyses.
Results: Serum miR-124 levels were significantly decreased in patients with PDAC. Serum levels of miR-124 distinguished PDAC from chronic pancreatitis (P |
| doi_str_mv | 10.1080/09674845.2016.1220706 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_09674845_2016_1220706</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1846368437</sourcerecordid><originalsourceid>FETCH-LOGICAL-c394t-cf1c7bff139244b4bec7402724f15259c8cbd5f138fc02535e4b6b30b694ab323</originalsourceid><addsrcrecordid>eNp90U1rHCEYB3ApDclmk4_QMtBLL7PxXefWkuYNFgKhvUbU0WCY0a3OEPLt47CbHnrIScTf8_jw_AH4guAGQQkvYMcFlZRtMER8gzCGAvJPYIWpoC2UHf8MVotpF3QCTkt5hhB1WPBjcIJFhzElcAUef6WXmN3TPOgppNgk34zhoUWYNrvs-mCn0uxSyvWWnmIqoTQhNjsdbXa1wjb9bCc9NLp3MVmdbYhp1BVMwcWpnIEjr4fizg_nGvy5vvp9edtu72_uLn9uW0s6OrXWIyuM94h0mFJDjbOCQiww9Yhh1llpTc_qs_QWYkaYo4YbAg3vqDYEkzX4vu9bx_w7uzKpMRTrhkFHl-aikKSccEmJqPTbf_Q5zTnW6apigklJ8KLYXtmcSsnOq10Oo86vCkG1BKDeA1BLAOoQQK37eug-m9H1_6reN17Bjz0I0ac86peUh15N-nVI2ee611AU-fiPN4gLlJM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1857588327</pqid></control><display><type>article</type><title>Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients</title><source>MEDLINE</source><source>EZB Electronic Journals Library</source><creator>Sun, BoLin ; Liu, Xiaogang ; Gao, Yewu ; Li, Li ; Dong, ZhenLing</creator><creatorcontrib>Sun, BoLin ; Liu, Xiaogang ; Gao, Yewu ; Li, Li ; Dong, ZhenLing</creatorcontrib><description>Background and aims: miRNA-124 (miR-124) expression was known to be downregulated in patients with pancreatic ductal adenocarcinoma (PDAC). Downregulation of miR-124 was significantly associated with poor prognosis in patients with PDAC. Recent studies have shown that circulating miRNAs could be the potential biomarkers for invasive diagnostic as well as prognostic purposes. The purpose of the current study was to characterise the serum miR-124 levels and assess the clinical significance of serum miR-124 in patients with PDAC.
Methods: Using quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) assays, serum miR-124 levels were determined in serum from 126 patients with PDAC (53 resectable pancreatic cancer and 73 unresectable pancreatic cancer), 28 chronic pancreatitis patients and 47 healthy control individuals. The prognostic significance of miR-124 and other clinicopathological variables was determined using univariate and multivariate analyses.
Results: Serum miR-124 levels were significantly decreased in patients with PDAC. Serum levels of miR-124 distinguished PDAC from chronic pancreatitis (P < 0.001) and healthy control subjects (P < 0.001). Low serum levels of miR-124 were significantly associated with lymph node metastasis, tumour node metastasis (TNM) stage and shorter survival time after surgery. In multivariate analysis, serum miR-124 (P = 0.001, HR: 2.47, 95% CI: 1.25-4.05), high TNM stage (P = 0.001, HR = 3.24, 95% CI: 2.03-8.08) and lymph node metastasis (P = 0.015, HR = 1.66, 95% CI: 1.02-3.13) were significant predictors.
Conclusions: Serum miR-124 levels have utility as diagnostic biomarkers in patients with PDAC. These findings suggest, for the first time, that serum miR-124 levels may have prognostic impact in patients with PDAC.</description><identifier>ISSN: 0967-4845</identifier><identifier>EISSN: 2474-0896</identifier><identifier>DOI: 10.1080/09674845.2016.1220706</identifier><identifier>PMID: 27922430</identifier><language>eng</language><publisher>England: Taylor & Francis</publisher><subject>Adult ; Aged ; Biomarkers ; Biomarkers, Tumor - blood ; Biomarkers, Tumor - genetics ; Cancer therapies ; Carcinoma, Pancreatic Ductal - blood ; Carcinoma, Pancreatic Ductal - diagnosis ; Carcinoma, Pancreatic Ductal - genetics ; Cell cycle ; Chemotherapy ; diagnosis ; Diagnosis, Differential ; Disease ; Down-Regulation ; Female ; Gene Expression ; Hospitals ; Humans ; Kaplan-Meier Estimate ; Lymphatic system ; Male ; marker ; Medical prognosis ; Metastasis ; MicroRNAs - blood ; MicroRNAs - genetics ; Middle Aged ; miR-124 ; Multivariate Analysis ; Pancreatic cancer ; Pancreatic ductal adenocarcinoma ; Pancreatic Neoplasms - blood ; Pancreatic Neoplasms - diagnosis ; Pancreatic Neoplasms - genetics ; Pancreatitis, Chronic - blood ; Pancreatitis, Chronic - diagnosis ; Pancreatitis, Chronic - genetics ; Patients ; Prognosis ; Reverse Transcriptase Polymerase Chain Reaction ; ROC Curve ; Studies ; Tumors</subject><ispartof>British journal of biomedical science, 2016-10, Vol.73 (4), p.152-157</ispartof><rights>2016 British Journal of Biomedical Science 2016</rights><rights>Copyright Taylor & Francis Ltd. 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c394t-cf1c7bff139244b4bec7402724f15259c8cbd5f138fc02535e4b6b30b694ab323</citedby><cites>FETCH-LOGICAL-c394t-cf1c7bff139244b4bec7402724f15259c8cbd5f138fc02535e4b6b30b694ab323</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27922430$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sun, BoLin</creatorcontrib><creatorcontrib>Liu, Xiaogang</creatorcontrib><creatorcontrib>Gao, Yewu</creatorcontrib><creatorcontrib>Li, Li</creatorcontrib><creatorcontrib>Dong, ZhenLing</creatorcontrib><title>Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients</title><title>British journal of biomedical science</title><addtitle>Br J Biomed Sci</addtitle><description>Background and aims: miRNA-124 (miR-124) expression was known to be downregulated in patients with pancreatic ductal adenocarcinoma (PDAC). Downregulation of miR-124 was significantly associated with poor prognosis in patients with PDAC. Recent studies have shown that circulating miRNAs could be the potential biomarkers for invasive diagnostic as well as prognostic purposes. The purpose of the current study was to characterise the serum miR-124 levels and assess the clinical significance of serum miR-124 in patients with PDAC.
Methods: Using quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) assays, serum miR-124 levels were determined in serum from 126 patients with PDAC (53 resectable pancreatic cancer and 73 unresectable pancreatic cancer), 28 chronic pancreatitis patients and 47 healthy control individuals. The prognostic significance of miR-124 and other clinicopathological variables was determined using univariate and multivariate analyses.
Results: Serum miR-124 levels were significantly decreased in patients with PDAC. Serum levels of miR-124 distinguished PDAC from chronic pancreatitis (P < 0.001) and healthy control subjects (P < 0.001). Low serum levels of miR-124 were significantly associated with lymph node metastasis, tumour node metastasis (TNM) stage and shorter survival time after surgery. In multivariate analysis, serum miR-124 (P = 0.001, HR: 2.47, 95% CI: 1.25-4.05), high TNM stage (P = 0.001, HR = 3.24, 95% CI: 2.03-8.08) and lymph node metastasis (P = 0.015, HR = 1.66, 95% CI: 1.02-3.13) were significant predictors.
Conclusions: Serum miR-124 levels have utility as diagnostic biomarkers in patients with PDAC. These findings suggest, for the first time, that serum miR-124 levels may have prognostic impact in patients with PDAC.</description><subject>Adult</subject><subject>Aged</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - blood</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Cancer therapies</subject><subject>Carcinoma, Pancreatic Ductal - blood</subject><subject>Carcinoma, Pancreatic Ductal - diagnosis</subject><subject>Carcinoma, Pancreatic Ductal - genetics</subject><subject>Cell cycle</subject><subject>Chemotherapy</subject><subject>diagnosis</subject><subject>Diagnosis, Differential</subject><subject>Disease</subject><subject>Down-Regulation</subject><subject>Female</subject><subject>Gene Expression</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Lymphatic system</subject><subject>Male</subject><subject>marker</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>MicroRNAs - blood</subject><subject>MicroRNAs - genetics</subject><subject>Middle Aged</subject><subject>miR-124</subject><subject>Multivariate Analysis</subject><subject>Pancreatic cancer</subject><subject>Pancreatic ductal adenocarcinoma</subject><subject>Pancreatic Neoplasms - blood</subject><subject>Pancreatic Neoplasms - diagnosis</subject><subject>Pancreatic Neoplasms - genetics</subject><subject>Pancreatitis, Chronic - blood</subject><subject>Pancreatitis, Chronic - diagnosis</subject><subject>Pancreatitis, Chronic - genetics</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Reverse Transcriptase Polymerase Chain Reaction</subject><subject>ROC Curve</subject><subject>Studies</subject><subject>Tumors</subject><issn>0967-4845</issn><issn>2474-0896</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp90U1rHCEYB3ApDclmk4_QMtBLL7PxXefWkuYNFgKhvUbU0WCY0a3OEPLt47CbHnrIScTf8_jw_AH4guAGQQkvYMcFlZRtMER8gzCGAvJPYIWpoC2UHf8MVotpF3QCTkt5hhB1WPBjcIJFhzElcAUef6WXmN3TPOgppNgk34zhoUWYNrvs-mCn0uxSyvWWnmIqoTQhNjsdbXa1wjb9bCc9NLp3MVmdbYhp1BVMwcWpnIEjr4fizg_nGvy5vvp9edtu72_uLn9uW0s6OrXWIyuM94h0mFJDjbOCQiww9Yhh1llpTc_qs_QWYkaYo4YbAg3vqDYEkzX4vu9bx_w7uzKpMRTrhkFHl-aikKSccEmJqPTbf_Q5zTnW6apigklJ8KLYXtmcSsnOq10Oo86vCkG1BKDeA1BLAOoQQK37eug-m9H1_6reN17Bjz0I0ac86peUh15N-nVI2ee611AU-fiPN4gLlJM</recordid><startdate>20161001</startdate><enddate>20161001</enddate><creator>Sun, BoLin</creator><creator>Liu, Xiaogang</creator><creator>Gao, Yewu</creator><creator>Li, Li</creator><creator>Dong, ZhenLing</creator><general>Taylor & Francis</general><general>Taylor & Francis Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>20161001</creationdate><title>Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients</title><author>Sun, BoLin ; Liu, Xiaogang ; Gao, Yewu ; Li, Li ; Dong, ZhenLing</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c394t-cf1c7bff139244b4bec7402724f15259c8cbd5f138fc02535e4b6b30b694ab323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - blood</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Cancer therapies</topic><topic>Carcinoma, Pancreatic Ductal - blood</topic><topic>Carcinoma, Pancreatic Ductal - diagnosis</topic><topic>Carcinoma, Pancreatic Ductal - genetics</topic><topic>Cell cycle</topic><topic>Chemotherapy</topic><topic>diagnosis</topic><topic>Diagnosis, Differential</topic><topic>Disease</topic><topic>Down-Regulation</topic><topic>Female</topic><topic>Gene Expression</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Lymphatic system</topic><topic>Male</topic><topic>marker</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>MicroRNAs - blood</topic><topic>MicroRNAs - genetics</topic><topic>Middle Aged</topic><topic>miR-124</topic><topic>Multivariate Analysis</topic><topic>Pancreatic cancer</topic><topic>Pancreatic ductal adenocarcinoma</topic><topic>Pancreatic Neoplasms - blood</topic><topic>Pancreatic Neoplasms - diagnosis</topic><topic>Pancreatic Neoplasms - genetics</topic><topic>Pancreatitis, Chronic - blood</topic><topic>Pancreatitis, Chronic - diagnosis</topic><topic>Pancreatitis, Chronic - genetics</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Reverse Transcriptase Polymerase Chain Reaction</topic><topic>ROC Curve</topic><topic>Studies</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sun, BoLin</creatorcontrib><creatorcontrib>Liu, Xiaogang</creatorcontrib><creatorcontrib>Gao, Yewu</creatorcontrib><creatorcontrib>Li, Li</creatorcontrib><creatorcontrib>Dong, ZhenLing</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Biological Sciences</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Science Journals</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of biomedical science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sun, BoLin</au><au>Liu, Xiaogang</au><au>Gao, Yewu</au><au>Li, Li</au><au>Dong, ZhenLing</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients</atitle><jtitle>British journal of biomedical science</jtitle><addtitle>Br J Biomed Sci</addtitle><date>2016-10-01</date><risdate>2016</risdate><volume>73</volume><issue>4</issue><spage>152</spage><epage>157</epage><pages>152-157</pages><issn>0967-4845</issn><eissn>2474-0896</eissn><abstract>Background and aims: miRNA-124 (miR-124) expression was known to be downregulated in patients with pancreatic ductal adenocarcinoma (PDAC). Downregulation of miR-124 was significantly associated with poor prognosis in patients with PDAC. Recent studies have shown that circulating miRNAs could be the potential biomarkers for invasive diagnostic as well as prognostic purposes. The purpose of the current study was to characterise the serum miR-124 levels and assess the clinical significance of serum miR-124 in patients with PDAC.
Methods: Using quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) assays, serum miR-124 levels were determined in serum from 126 patients with PDAC (53 resectable pancreatic cancer and 73 unresectable pancreatic cancer), 28 chronic pancreatitis patients and 47 healthy control individuals. The prognostic significance of miR-124 and other clinicopathological variables was determined using univariate and multivariate analyses.
Results: Serum miR-124 levels were significantly decreased in patients with PDAC. Serum levels of miR-124 distinguished PDAC from chronic pancreatitis (P < 0.001) and healthy control subjects (P < 0.001). Low serum levels of miR-124 were significantly associated with lymph node metastasis, tumour node metastasis (TNM) stage and shorter survival time after surgery. In multivariate analysis, serum miR-124 (P = 0.001, HR: 2.47, 95% CI: 1.25-4.05), high TNM stage (P = 0.001, HR = 3.24, 95% CI: 2.03-8.08) and lymph node metastasis (P = 0.015, HR = 1.66, 95% CI: 1.02-3.13) were significant predictors.
Conclusions: Serum miR-124 levels have utility as diagnostic biomarkers in patients with PDAC. These findings suggest, for the first time, that serum miR-124 levels may have prognostic impact in patients with PDAC.</abstract><cop>England</cop><pub>Taylor & Francis</pub><pmid>27922430</pmid><doi>10.1080/09674845.2016.1220706</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0967-4845 |
| ispartof | British journal of biomedical science, 2016-10, Vol.73 (4), p.152-157 |
| issn | 0967-4845 2474-0896 |
| language | eng |
| recordid | cdi_crossref_primary_10_1080_09674845_2016_1220706 |
| source | MEDLINE; EZB Electronic Journals Library |
| subjects | Adult Aged Biomarkers Biomarkers, Tumor - blood Biomarkers, Tumor - genetics Cancer therapies Carcinoma, Pancreatic Ductal - blood Carcinoma, Pancreatic Ductal - diagnosis Carcinoma, Pancreatic Ductal - genetics Cell cycle Chemotherapy diagnosis Diagnosis, Differential Disease Down-Regulation Female Gene Expression Hospitals Humans Kaplan-Meier Estimate Lymphatic system Male marker Medical prognosis Metastasis MicroRNAs - blood MicroRNAs - genetics Middle Aged miR-124 Multivariate Analysis Pancreatic cancer Pancreatic ductal adenocarcinoma Pancreatic Neoplasms - blood Pancreatic Neoplasms - diagnosis Pancreatic Neoplasms - genetics Pancreatitis, Chronic - blood Pancreatitis, Chronic - diagnosis Pancreatitis, Chronic - genetics Patients Prognosis Reverse Transcriptase Polymerase Chain Reaction ROC Curve Studies Tumors |
| title | Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T02%3A00%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Downregulation%20of%20miR-124%20predicts%20poor%20prognosis%20in%20pancreatic%20ductal%20adenocarcinoma%20patients&rft.jtitle=British%20journal%20of%20biomedical%20science&rft.au=Sun,%20BoLin&rft.date=2016-10-01&rft.volume=73&rft.issue=4&rft.spage=152&rft.epage=157&rft.pages=152-157&rft.issn=0967-4845&rft.eissn=2474-0896&rft_id=info:doi/10.1080/09674845.2016.1220706&rft_dat=%3Cproquest_cross%3E1846368437%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1857588327&rft_id=info:pmid/27922430&rfr_iscdi=true |